Phase 3 study of oral selinexor as maintenance therapy after first-line chemotherapy for advanced/ recurrent endometrial cancer

Patients with first-line metastatic or recurrent endometrial cancer (EC) are usually treated wth paclitaxel and carboplatin, but most have short-term disease control and a poor prognosis. The multinational phase 3 ENGOT-EN5/GOG-3055/SIENDO study evaluated oral selinexor (80 mg once weekly) versus placebo maintenance therapy in patients with advanced or recurrent EC in partial or complete remission after first-line chemotherapy. The study found significantly prolonged progression-free survival with selinexor versus placebo, with a manageable and tolerable safety profile. Pre-specified subgroup analyses identified wild-ype TP53 and pMMR as important predictors of selinexor efficacy.